Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

(2020) Stephen T. Oh et al.   Blood Advances

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

(2018) Tiziano Barbui et al.   Blood Cancer Journal

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

(2018) Gunnar Birgegard et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Use of the Functional Assessment of Cancer Therapy−Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

(2014) Ayalew Tefferi et al.   CLINICAL THERAPEUTICS

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

(2013) Animesh Pardanani et al.   AMERICAN JOURNAL OF HEMATOLOGY

Hepcidin and iron homeostasis

(2012) Tomas Ganz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostication in Primary Myelofibrosis

(2011) Francisco Cervantes et al.   Current Hematologic Malignancy Reports